Third, this stock provides stability to investors' portfolios in the event the economy takes a turn for the worse in the new ...

AI agents are moving rapidly from experimentation to everyday business use, but choosing the right platform can feel ...

According to Gartner, 58% of finance functions employed AI in 2024—a 21-percentage-point jump from the prior year. PwC ...

UTime Limited (Nasdaq: WTO), a global technology company engaged in the design and development of mobile devices today announced a major commercial breakthrough. UTime’s Hong Kong subsidiary, UTime ...

Alibaba’s Qwen team of AI researchers — already having a banner year with numerous powerful open source AI model releases — ...

The top 10 PharmTech videos of the year cover advanced therapies, high-concentration biologics, major mergers and ...

Alphabet is the most complete end-to-end AI company on the planet, and the advantages of its vertical integration and its ...

Traditional cloud architectures are buckling under the weight of generative AI. To move from pilots to production, ...

Gemini's mini app builder uses Opal tech to deliver a new kind of Gem, and it's a game-changer for quick and simple web ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...